Rein Therapeutics Inc. – Filings and Transcripts

NASDAQ: RNTX
Share price (3/27/26): $1.25
Market cap (3/27/26): $35.0 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024 – amended

Prospectuses and Registrations Filter

Initial registration of new securities

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Shelf registration

Prospectus supplement for primary offering

Ownership Filter

Voss Capital, LP

Voss Capital, LP, Voss Advisors GP, LLC, Cocke Travis W., Voss Value-Oriented Special Situations Fund, LP, Voss Value Master Fund, LP

Voss Capital, LP, Voss Advisors GP, LLC, Cocke Travis W., Voss Value-Oriented Special Situations Fund, LP, Voss Value Master Fund, LP

Voss Capital, LP, Voss Advisors GP, LLC, Cocke Travis W., Voss Value-Oriented Special Situations Fund, LP, Voss Value Master Fund, LP

Voss Capital, LP

News Filter

Material Definitive Agreement, New Financial Obligation or Off-Balance Sheet Arrangement, Unregistered Sales of Equity Securities, Financial Statements or Exhibits

Change in Directors, Officers or Compensation

Material Definitive Agreement, New Financial Obligation or Off-Balance Sheet Arrangement, Unregistered Sales of Equity Securities, Financial Statements or Exhibits

Termination of Material Definitive Agreement

Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Notice of effectiveness

Correspondence with the SEC